EIT Health 2027 Grants Key Provisions and Implications

EIT Health 2027 Grants launch a structured funding pathway through the Transformative Health Instrument that anchors project eligibility to Horizon Europe association rules and requires commercializing entities to demonstrate minimum operational capacity.

Funding remains limited to organizations legally registered in qualifying jurisdictions, with all projects running strictly from 1 January 2027 to 31 December 2027 and awards ranging between 300,000 and 500,000 euros. Recipients must also sign a Grant-to-Options-to-Equity Agreement that converts support into future equity stakes, safeguarding long-term sustainability for the Knowledge and Innovation Community.

Evaluation and Verification Process

Eligibility checks begin with staff screening and move to independent expert scoring in two stages, including remote review by three external evaluators followed by a pitch session with additional EIT Health specialists. Financial capacity reviews rely on third-party audits of legal, administrative, and fiscal documents, while every applicant organization must hold a Participant Identification Code. Cost rules follow the Annotated Model Grant Agreement for both pre-financing and reimbursement phases.

Ad

Access Patterns Across Regions

United Kingdom and Swiss entities now enjoy equivalent status to Horizon Europe participants after recent association agreements, yet Canadian applicants encounter effective exclusion because the 60,000-euro cap falls below the call’s minimum threshold. Hungarian public-interest trusts stay barred from funded roles under current Council measures, and residency rules apply only to legal entities rather than individual team members. Co-funding operates through minimum-percentage calculations that accept mixed sources as long as double-funding is avoided.

Equity Mechanisms and Accountability

The equity-conversion terms within the Grant-to-Options-to-Equity Agreement create a standardized route that ties EIT Health 2027 Grants returns to future financing events and shapes how recipient companies design convertible instruments or change-of-control deals. Valuation at the 15 January 2030 maturity defaults to the most favorable prior terms or mutual agreement, while mandatory progress reporting and audit clauses reinforce accountability across European health-innovation projects.